Mark Mansour has more than two decades of experience handling federal Food and Drug Administration (FDA) regulatory matters. He has significant experience working with clients in the food, pharmaceutical, medical device, dietary supplements and cosmetic industries to develop and implement strategies for regulatory approvals, compliance and enforcement actions, crisis management, rulemaking and public policy issues. He counsels corporations and organizations on how to negotiate effectively with government agencies in the United States and key global markets.
Mark is a leader in the development of regulatory pathway strategies for approvals in the United States and many international markets. He has been actively involved with industry and government to achieve solutions to issues such as the regulation of biotechnology and nanotechnology and also is active in domestic and international industry groups involving the key regulated industries. Throughout his seasoned career, he has taken a lead role in drafting industry comments in response to key rulemaking activities.
Mark is a member of Locke Lord’s Cannabis law team and counsels clients in the medical and recreational cannabis space in multiple states across the country. Mark advises both public and private cannabis companies regarding federal and state regulation. He is part of a multidisciplinary team at the firm that provides services and guidance to legal marijuana businesses in a variety of areas.
Mark is recognized as one of the most effective crisis managers in the food, drug and medical device fields, having been actively involved in the representation of clients affected by many of the largest and most complex recalls since 1997. He has also assisted clients in managing numerous Federal Trade Commission consumer protection matters, including investigations, enforcement actions, negotiations and consent decrees for marketing, advertising and privacy matters, as well as advertising disputes before the National Advertising Division of the Better Business Bureaus.
The regulation of cannabis is one of the most controversial issues facing the U.S. Food and Drug Administration (FDA) and the states. FDA held a public meeting on May 31, 2019, and the result was inconclusive regarding next steps. This webinar will d...